Optimizing Treatment Strategies: A Comprehensive Approach to Primary Biliary Cholangitis and Pruritus

Faculty Information

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP

Professor of Pharmacy Practice

Massachusetts College of Pharmacy and Health Sciences (MCPHS) University

School of Pharmacy-Worcester/Manchester

Worcester, Massachusetts

Anastasia Abramson, PharmD, MBA

Manager of Clinical Strategy and Patient Engagement

PANTHERx Rare Pharmacy

Pittsburgh, Pennsylvania

Faculty and Staff Disclosures

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP; and **Anastasia Abramson, PharmD, MBA,** have no relevant financial relationships with commercial interests to disclose.

***Pharmacy Times* Continuing Education™ Planning Staff:** Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no financial relationships with commercial interests to disclose.

An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

PTce

Pharmacy Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-344-L01-P.

Release Date: December 12, 2024

Activity Type: Application

Fee: Free

How to Obtain Credit

Instructions on how to obtain credit for this activity will be provided at the end of the day.

This activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Optimizing Treatment Strategies: A Comprehensive Approach to Primary Biliary Cholangitis and Pruritus

Educational Objectives

After completion of this activity, participants will be able to:

- Examine the burden of illness associated with primary biliary cholangitis (PBC), including the significant impact of pruritus and fatigue on patients' quality of life
- Analyze current and potential novel therapies for cholestatic pruritus, considering their mechanism of action, efficacy data, and safety profile, to inform patient care decisions
- Identify pharmacist-led interventions to improve clinical outcomes and alleviate symptoms in patients with PBC

Pretest Questions

Pretest Question 1

Which statement is TRUE regarding itching in primary biliary cholangitis (PBC)?

A. The severity of itching correlates with PBC severity.
B. Itching occurs only in the later stages of PBC.
C. The underlying cause of itching in PBC has been fully elucidated.
D. Itching significantly impacts quality of life in patients with PBC.

Pretest Question 2

A 58-year-old woman with a history of PBC presents to your clinic for follow-up. She has been on ursodeoxycholic acid (UDCA) at a dose of 13 mg/kg/day for the past year. Her recent laboratory results show an ALP level of 200 U/L (normal range: 30-120 U/L) and a total bilirubin level of 1.2 mg/dL (normal range: 0.1-1.0 mg/dL). She reports persistent fatigue and moderate pruritus despite treatment with cholestyramine.

What is the most appropriate next step in managing this patient?

A. Continue UDCA monotherapy and re-evaluate in 6 months.

B. Increase the dose of UDCA to 15 mg/kg/day.

C. Initiate treatment with elafibranor 80 mg daily.

D. Initiate treatment with obeticholic acid 5 mg daily.

Pretest Question 3

GC is a 58-year-old woman diagnosed with PBC who has a referral sent to your pharmacy for obeticholic acid. During your initial counseling, GC shares that she has not had any issues with UDCA, but her doctor advised her ALP and bilirubin are not where they should be. GC states that lately she has had some itching but wearing cotton clothing usually helps. What is the most appropriate next step?

A. Inform GC she should discontinue UDCA because it isn't helping.
B. Document that GC has mild itching that is helped by wearing cotton. Re-assess GC periodically for any changes in itching severity to identify if additional lifestyle changes or medications are necessary.
C. Document that GC has mild itching that is helped by wearing cotton.
D. Advise GC she should start on cholestyramine right away, taking the obeticholic acid at least 4 hours before or 4 hours after the cholestyramine dose.

Pretest Question 4

Before participating in this activity, how confident are you in your knowledge to improve clinical outcomes and alleviate symptoms in patients with PBC?

A. Not at all
B. Somewhat
C. Moderately
D. Very
E. Extremely

Optimizing Treatment Strategies: A Comprehensive Approach to PBC and Pruritus

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP

Outline

- Introduction to primary biliary cholangitis (PBC)
- Impact of pruritus and fatigue on quality of life
- Treatment options for PBC
  - Treatment guidelines
  - Pharmacotherapy
- Upcoming treatments in the pipeline
- Considerations for pharmacists
- Conclusion

Primary Biliary Cholangitis (PBC)

- Chronic autoimmune disease of the liver
- Slowly progressing illness resulting in cirrhosis and hepatic failure if untreated
- Pathophysiology
  - Chronic, nonsuppurative destruction of small- and medium-sized bile ducts
    - Secondary to infiltration of lymphocytes
  - Bile stasis results
    - Fewer bile ducts available, resulting in ductule proliferation
  - Fibrosis and periportal bridging
  - Ultimately results in cirrhosis

Tanaka A et al. *Lancet.* 2024;404:1053-1066; Befeker AS, Bacon BR. *Harrison's Principles of Internal Medicine,* 21st ed. Loscalzo J et al. McGraw Hill, 2022.

Epidemiology of PBC

Primarily impacts women 40-70 years of age

- Peaks at 60-79 years of age
- 4:1 female:male ratio

North America has the highest incidence and prevalence

- Incidence
  - 2.75 per 100,000 people/year
- Prevalence
  - 21.81 per 100,000 people/year

Prevalence has continued to rise over the past 20 years

- Likely due to pharmacotherapy and earlier diagnosis

Tanaka A et al. *Lancet.* 2024;404:1053-1066.

Risk Factors for PBC

Genetic susceptibility

- HLA regions
- Non-HLA alleles
- Estrogen stimulation of the immune system
  - Cholangiocytes have estrogen receptors
  - X chromosome locus

Environmental factors

- Cigarette smoking
- Urinary tract infections
- Hair dye, nail polish
- Non-hygienic environments
- Decreased diversity of the gut microbiome

Tanaka A et al. *Lancet.* 2024;404:1053-1066.

Symptoms of PBC

Jaundice

Cognitive symptoms

- Difficulty with concentration and memory

Fatigue

- Affects more than 50% of patients
- Not correlated with disease severity
- Unknown mechanism
  - Sleep disturbance, depression

Pruritus

- Itching

Tanaka A et al. *Lancet.* 2024;404:1053-1066; Befeker AS, Bacon BR. *Harrison's Principles of Internal Medicine*, 21st ed. Loscalzo J et al. McGraw Hill, 2022.

Pruritus

- Impacts 20%-80% of patients
- Clinical course fluctuates
- Can occur early in PBC
  - Increases as PBC progresses
- Often more bothersome in the evening
- Can be debilitating
  - Will discuss quality of life impacts later
- Unknown cause
  - Although many substances could be the underlying factor
    - Lysophosphatidic acid, bile acids, endogenous opioids

Tanaka A et al. *Lancet*. 2024;404:1053-1066; Befeker AS, Bacon BR. *Harrison's Principles of Internal Medicine,* 21st ed. Loscalzo J et al. McGraw Hill, 2022.

Additional Complications of PBC

- Hypercholesterolemia
  - Due to cholestasis secondary to cholangitis
  - Statins used just when metabolic syndrome is present
- Osteoporosis
  - 3.3-fold increased risk compared with people without PBC
  - Due to decreased bone formation
  - Denosumab has data showing efficacy for this population
- Hepatocellular carcinoma (HCC)
  - 3.4-3.6 cases per 1000 patient-years
  - Risk factors
    - Male sex
    - Increased alcohol use
    - Advanced histologic stage
    - Presence of diabetes
    - Overweight
    - Treatment response to UDCA

Tanaka A et al. *Lancet*. 2024;404:1053-1066.

Physical Examination

- Physical findings
  - Jaundice
  - Hepatomegaly
  - Splenomegaly
  - Ascites
  - Edema
- Unique physical findings
  - Hyperpigmentation
  - Xanthelasma
  - Xanthomata







Befeker AS, Bacon BR. *Harrison's Principles of Internal Medicine,* 21st ed. Loscalzo J et al. McGraw Hill, 2022. Images: Wikimedia Commons. Available athttps://commons.wikimedia.org/wiki/Main_Page.

Laboratory Findings

- Cholestatic findings
  - Elevated alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT)
  - Mild increase in AST and ALT
  - Increased IgM
  - Elevated bilirubin
    - Once patient progresses to cirrhosis
  - Bone marrow suppression
    - Once patient develops portal hypertension and splenomegaly
  - Up to 10% of patients will appear to have autoimmune hepatitis
    - “Overlap syndrome”

Corpechot C. *Clin Res Hepatol Gastroenterol.* 2022;46:1-8; Befeker AS, Bacon BR. *Harrison’s Principles of Internal Medicine*, 21st ed. Loscalzo J et al. McGraw Hill, 2022.

Diagnosis

AMA testing

- Anti-mitochondrial antibodies
  - 1:40 is positive
  - Negative in 5%-10% of patients
    - Liver biopsy utility limited
    - If AMA negative with cholestatic changes in liver enzymes, do cholangiography

Biochemical

- ALP elevated to >1.5x upper limit of normal (ULN)
- GGT elevated to >3x ULN

Corpechot C. *Clin Res Hepatol Gastroenterol* 2022;46:1-8; Befeker AS, Bacon BR. *Harrison's Principles of Internal Medicine,* 21st ed. Loscalzo J et al. McGraw Hill, 2022.

PBC Severity Assessment

Pruritus assessment on a visual analog scale

- ≥4 out of 10

Lab assessment

- Total and conjugated bilirubin
- Albumin
- ALP
- AST and ALT
- Platelet count

Liver assessment

- Ultrasound
- Vibration-controlled transient elastography

Corpechot C. *Clin Res Hepatol Gastroenterol* 2022;46:1-8.

Impact of Pruritus and Fatigue on Quality of Life: TARGET-PBC

- Longitudinal observational cohort of patients living with PBC in the US
- Described
  - Population
  - Impact of pruritus on quality of life
  - Management in the real-world setting
- Asked patients to complete patient-reported outcome (PRO) surveys every 6 months
  - PBC-40
  - 5-D Itch
  - PROMIS fatigue survey
- Included data from 211 people with PBC across 38 clinics who completed PRO surveys

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

Impact of Pruritus and Fatigue on Quality of Life TARGET-PBC

- Patient population characteristics
  - 91.9% female
  - Median age 60 years
  - 87.2% White
  - 35.1% with cirrhosis
  - 87.2% with positive AMA titer

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

Impact of Pruritus and Fatigue on Quality of Life TARGET-PBC Results

- PBC-40
  - Comprises 40 questions that focus on different domains in PBC
    - Includes itch, fatigue, cognition, emotional
    - Maximum score 15 for itch
      - Score of ≥7 considered clinically significant (CS) itch
  - Overall, 81% (170/211) of the cohort experienced pruritus
    - 63% mild itch
    - 37% CS itch
  - Patients with CS itch scored 80% higher in the cognitive and social domains
    - Indicated more distress occurred than in patients without itching

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

Impact of Pruritus and Fatigue on Quality of Life TARGET-PBC Results

- 5-D Itch
  - Asks about itch with respect to
    - Degree, duration, disability, direction, distribution
    - Scored 5-25
  - 20% of patients with CS itch had >12 hours of itching per day
  - Most frequent areas affected
    - Head/scalp
    - Lower legs
    - Back
    - Palms of hands/soles of feet
  - 88% reported disrupted sleep

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

Impact of Pruritus and Fatigue on Quality of Life TARGET-PBC Results

- PROMIS fatigue survey
  - Survey uses a Likert scale to have patients score the effects of itch
    - Frequency
    - Duration
    - Intensity
    - Physical
    - Mental
    - Social
  - Scores added up and cross-referenced on a table to determine a score
  - Higher level of fatigue reported in patients with CS itch
    - Median score of 61 compared with 50 in the mild- and no-itch groups

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

TARGET-PBC Assessment of Pruritus Treatments

- 51% of patients with CS itch received treatment vs 28% with mild itch
- 33% of patients with CS itch never received treatment
  - Based on their medical records
- 97% of all patients with PBC received UDCA, regardless of itch severity
- 16% received obeticholic acid (OCA) alone or with other treatments
- 66% of patients with CS itch received antihistamines vs 73% with mild itch
- 9% of all patients received bile acid resins

Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

TARGET-PBC Conclusions

- Prevalence of itch was high in this population
- Patients with CS itch were more likely to have advanced PBC and significantly worse quality of life
- Itch in people with PBC is undertreated
  - Often treated with non–first-line agents
    - Only 9% of patients received bile acid resins, despite AASLD and EASL recommendations
- Study limitations
  - Potential selection bias
  - OCA can cause itch and could have confounded the data

AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver; Mayo MJ et al. *Dig Dis Sci.* 2023;68(3):995-1005.

Pharmacotherapeutic Management of PBC

Linda M. Spooner, PharmD, BCPS, FASHP, FCCP

Principles of Pharmacotherapy for PBC

- Two sets of guidelines provide recommendations
  - American Association for the Study of Liver Diseases (AASLD)
    - Published in 2018
      - Focused update in 2021
    - Concise
    - Focuses on diagnosis and treatment considerations
  - European Association for the Study of the Liver (EASL)
    - Published in 2017
    - Emphasizes personalized approach to care
- Some variation in treatment selection and monitoring

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Lindor KD et al. *Hepatology.* 2022;75:1012-1013; Hirschfield GM et al. *J Hepatol.* 2017;67:145-172.

2018 Practice Guidance from AASLD

- First-line therapy for all patients with PBC and abnormal liver enzymes
  - Ursodeoxycholic acid (UDCA)
    - 13-15 mg/kg/day PO in 2 divided doses or once daily
    - Assess lab response 12 months after starting treatment
      - To determine if second-line treatment is needed
- Obeticholic acid (OCA)
  - Second-line therapy
    - Inadequate response to UDCA
    - If intolerance to UDCA
  - Contraindicated in patients with advanced cirrhosis
- Fibrates
  - Off-label use for inadequate response to UDCA
  - Avoid in patients with decompensated liver disease

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Lindor KD et al. *Hepatology.* 2022;75:1012-1013.

2018 Practice Guidance from AASLD

- Management of fatigue
  - No data to support any recommendation
- Management of pruritus
  - Lifestyle modifications
  - Anion-exchange resins
    - Cholestyramine, colestipol, colesevalam
  - Rifampicin 150-300 mg BID
  - Opioid antagonist
    - Naltrexone 50 mg daily
  - Sertraline 75-100 mg daily
  - Phenobarbital
    - Worsens PBC fatigue
  - Antihistamines
    - Although PBC itch is not histamine related!
  - Notes that there are newer agents in the pipeline

Lindor KD et al. *Hepatology.* 2019;68(1):394-419.

2017 EASL Clinical Practice Guidelines

- Treatment goals
  - Prevent end-stage complications and manage PBC symptoms
- First-line therapy
  - UDCA 13-15 mg/kg/day
    - Assess biochemical response at 1 year
- Second-line therapy
  - OCA
    - For inadequate response to UDCA
  - Notes that many drugs are in the pipeline
- Does not provide recommendation for fibrates

Hirschfield GM et al. *J Hepatol.* 2017;67:145-172.

2017 EASL Clinical Practice Guidelines

- Treatment of fatigue
  - Manage exacerbating conditions
  - Coping strategies
- Treatment of pruritus
  - Supportive care
  - First-line: cholestyramine
  - Second-line: rifampicin
  - Third-line: naltrexone
- Organization of care
  - Structured follow-up for life
  - Individualized approach

Hirschfield GM et al. *J Hepatol.* 2017;67:145-172.

Ursodeoxycholic Acid (UDCA)

- FDA approved for PBC
  - 13-15 mg/kg/day with food
    - Can divide into 2 doses or given at bedtime to improve compliance
- Potential mechanism of action
  - Choleretic action
  - Stabilization of the biliary epithelium
  - Inhibition of NF-kß pro-inflammatory pathway
  - Reduction of bile acid concentration
  - Immunomodulation

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Fiorucci S et al. *Cells.* 2024;13:1580-1611.

Ursodeoxycholic Acid (UDCA)

- Efficacy
  - Reduces ALP, bilirubin, AST, ALT
  - Slows progression of hepatic fibrosis
  - Delays development of esophageal varices
  - Improves chances of survival without liver transplant
- Adverse effects
  - Weight gain (≈5 pounds in year 1)
  - Thinning hair
  - Loose stools

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Fiorucci S et al. *Cells.* 2024;13:1580-1611.

Ursodeoxycholic Acid (UDCA)

- Special considerations
  - Bile acid sequestrants and antacids
    - Require separation from UDCA to prevent absorption interactions
      - Administer UDCA 1 hour before or 4 hours after the interacting drug
  - Considered safe during pregnancy and breastfeeding
- Monitoring parameters
  - Response to treatment
    - Liver function tests
  - Adverse effects
  - Determination of need to discontinue/change therapy
    - Individualized approach

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Fiorucci S et al. *Cells.* 2024;13:1580-1611.

Obeticholic Acid (OCA)

- FDA approved for PBC
  - Initial dose: 5 mg PO daily
    - Increase to 10 mg PO daily after 3 months if inadequate reduction in ALP or total bilirubin
- Mechanism of action
  - Hydrophobic bile acid analog
  - Farsenoid X receptor (FXR) agonist
    - 100x more potent than the endogenous ligand
    - Modulates bile acid production, transport, secretion, metabolism
      - Limits production of bile acids
      - Results in choleresis
    - Prevents fibrosis
    - Anti-inflammatory

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Hirschfield GM et al. *J Hepatol.* 2017;67:145-172.

Obeticholic Acid (OCA)

- Efficacy
  - Biochemical response achieved in 46% of patients at 1 year
    - POISE criteria:
      - ALP reduction to less than 1.67x ULN
      - ALP reduction of at least 15% from baseline
      - Normalization of total bilirubin
    - Extension trials demonstrated that this response persisted
  - Proven to reduce liver transplantation and death
- Adverse effects
  - Pruritus
    - Dose dependent
    - Results in 10%-25% discontinuation rate
  - Elevation in LDL and reduction in HDL
    - Due to its mechanism of action

Lindor KD et al. *Hepatology.* 2019;68(1):394-419; Trivella J et al. *Hepatol Commun.* 2023;7(6):e0179.

Obeticholic Acid (OCA)

- Special considerations
  - Boxed warning
    - Contraindicated in patients with advanced cirrhosis
      - Decompensated or compensated cirrhosis with current or prior evidence of portal hypertension or decompensation
        - Encephalopathy
        - Coagulopathy
  - AASLD Guidance updated in 2021 to note this and revise the OCA recommendation
    - Careful monitoring of any patient with non-advanced cirrhosis
  - Separate dosing from bile acid sequestrants
    - As with UDCA
- Monitoring parameters
  - LFTs
  - PT/INR
  - Lipids
  - Adverse effects

Lindor KD et al. *Hepatology.* 2022;75:1012-1013; Trivella J et al. *Hepatol Commun.* 2023;7(6):e0179; Ocaliva. Prescribing information. Intercept Pharma, 2022. Accessed December 10, 2024. https://www.interceptpharma.com/wp-content/uploads/2023/08/Ocaliva_USPI_Clean_VV-REG-040954.pdf

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Fibrates

- Fenofibrate
  - Not FDA approved for PBC
  - PPAR-α agonist
    - Regulates bile acid production and transport
    - Promotes biliary secretion
    - Modulates immune system
    - Reduces inflammation via the NF-κB pathway
  - Reduces ALP and decreases itching
  - 200 mg/day in combination with UDCA and/or OCA
  - Drug interactions with statins, bile acid sequestrants
  - Monitoring parameters
    - Creatine phosphokinase, muscle pain/weakness

Chen Y et al. *Exp Opin Pharmacother.* 2024;25(13):1825-1834; Trivella J et al. *Hepatol Commun.* 2023;7(6):e0179; Trilipix. Prescribing information. Lupin Pharmaceuticals, 2019. Accessed December 10, 2024. fenofibric-acid-dr-caps-eq-trilipix-pi5-2019.pdf

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Nonfibrate

- Seladelpar
  - FDA approved for PBC
  - Highly selective PPAR-δ agonist
  - Dosing: 10 mg PO daily
- Mechanism of action
  - Activates PPAR-δ to result in
    - Suppression of CYP7A1
      - Involved in bile acid production
    - Reduction of TNF-α and IL-1β production
      - Involved in inflammation
    - Reduction of triglycerides, free fatty acids, and apolipoprotein B-100

Chen Y et al. *Exp Opin Pharmacother.* 2024;25(13):1825-1834; Caines A et al. *Exp Opin Pharmacother.* 2024;25(11):1517-1523.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonist: Seladelpar

- Clinical data
  - 2017 study assessing seladelpar for PBC
    - Effective in reducing ALP
    - Discontinued early due to 3 cases of ALT elevation in 200-mg group
  - 2022 open-label, 52-week trial of lower doses
    - ALP significantly reduced by week 12, then maintained through end of trial
    - Improved pruritus
      - 58% (5 mg) and 93% (10 mg) of patients with moderate to severe pruritus (≥40 on visual analog scale) had a 20-point decrease (p value not provided)
      - Significant improvement in 5-D Itch and PBC-40 surveys
  - ENHANCE: Phase 3 double-blind, randomized, placebo-controlled trial of 5 mg and 10 mg
    - Demonstrated dose-dependent improvement in biochemical markers and pruritus
      - 57.1% (5 mg) and 78.2% (10 mg) vs 12.5% (placebo) achieved the POISE criteria
        - $P < 0.0001$
      - Five-year extension study of the 2022 open-label trial and ENHANCE was terminated at 21 months due to histologic changes in patients with nonalcoholic steatohepatitis

Chen Y et al. *Exp Opin Pharmacother.* 2024;25(13):1825-1834; Kremer AE, et al. *Liver Int* 2022;42:112-123.; Hirschfield GM, et al. *Hepatol* 2023;78:397-415; Caines A et al. *Exp Opin Pharmacother.* 2024;25(11):1517-1523.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Seladelpar

- RESPONSE: Phase 3 double-blind, randomized, placebo-controlled trial
  - Included patients with or without UDCA
  - Excluded patients with advanced PBC and decompensated liver disease
  - 61.7% of patients taking 10 mg seladelpar vs 20% of patients in placebo group achieved the POISE criteria (difference 41.7 percentage points, 95% CI: 27.7 to 53.4, $P < 0.001$)
    - At month 12, 25% of patients taking seladelpar had normalized their ALP vs 0% in placebo group (difference 25 percentage points, 95% CI: 18.3 to 33.2, $P < 0.001$)
  - Significant reduction in itching in seladelpar group
  - No change in liver stiffness or fibrosis
  - Adverse effects noted more frequently in seladelpar group
    - Headache
    - Abdominal distension
    - COVID-19

Hirschfield GM, et al. *N Engl J* Med 2024; 390(9):783-94.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Seladelpar

- Adverse effects
  - Headache
  - Nausea
  - Abdominal distension
  - Dizziness
  - Fractures (4%)
    - Monitor bone mineral density
- Special considerations
  - Separate dosing from bile acid sequestrants by at least 4 hours
  - Substrate of CYP2C9 and CYP3A4
    - Avoid with strong CYP2C9 inhibitors
- Monitoring parameters
  - Effectiveness
  - Liver function tests
  - Bone health

Livdelzi. Prescribing information. Gilead Sciences; 2024. Accessed December 10, 2024. https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Nonfibrates

- Elafibranor
  - FDA approved for PBC
    - With or without UDCA
  - PPAR-α, -γ, and –δ agonist
  - Dosing: 80 mg PO once daily
- Mechanism of action
  - Not fully determined
  - Inhibits bile acid synthesis by activating PPAR-α and PPAR-δ

Chen Y et al. *Exp Opin Pharmacother.* 2024;25(13):1825-1834; Blair HA. *Drugs.* 2024;84:1143-1148.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Elafibranor

- Clinical data
  - Phase 2a randomized, double-blind, placebo-controlled trial over 12 weeks
    - Relative reduction in ALP levels from baseline
      - -48.3% elafibranor 80 mg, -40.6% elafibranor 120 mg, +3.2% placebo
        - P < 0.001 vs placebo
    - Biochemical response achieved in 53% elafibranor 80 mg, 36% elafibranor 120 mg, 0% placebo
      - ALP <1.5x ULN, ALP >40% reduction from baseline, normal total bilirubin
        - P < 0.001 vs placebo
  - ELATIVE: Phase 3 randomized, double-blind, placebo-controlled trial over 52 weeks
    - Biochemical response achieved in 51% of patients in elafibranor group vs 4% in placebo group
      - Difference of 47 percentage points (95% CI: 32 to 57, P<0.001)
      - ALP <1.67x ULN, ALP 15% reduction from baseline, normal total bilirubin
    - Normalization of ALP achieved in 15% of patients in elafibranor group vs 0% in placebo group
      - 15% difference (95% CI: 6 to 23, P=0.002)
    - Worst Itch Numeric Rating Scale: no significant difference from baseline
    - PBC-40 itch domain and 5-D Itch scale: appeared to favor elafibranor
      - Not statistically significant

Schattenberg JM, et al. *J* Hepatol. 2021;74:1344-54; Kowdley KV et al. *N Engl J Med.* 2024;360:795-805.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonists: Elafibranor

- Adverse effects
  - Fatigue
  - Pruritus
  - Myalgia, rhabdomyolysis
  - Drug-induced hepatic injury
  - Fractures (6%)
    - Monitor bone health
- Special considerations
  - Separate dosing of bile acid sequestrants by at least 4 hours
  - Substrate of multiple UGTs, weak inducer of CYP3A4
  - Increased risk of myopathy with concomitant statin use
- Monitoring parameters
  - As with seladelpar

UGT, uridine diphosphate (UDP)-glucuronosyltransferases.

Iqirvo Prescribing Information. Ipsen Biopharmaceuticals; 2024. Accessed December 10, 2024. https://d2rkmuse97gwnh.cloudfront.net/a88aa6d6-3ca0-4362-a711-d53c45ae33ff/c91c4c2d-fbd6-4dec-99db-66768cdb2b5c/c91c4c2d-fbd6-4dec-99db-66768cdb2b5c_source__v.pdf; Blair HA. *Drugs.* 2024;84:1143-1148.

PBC Treatments in the Pipeline
Ongoing Clinical Trials

- Volixibat
  - Apical sodium-dependent bile acid transporter (ASBT) inhibitor
  - Primary end point of phase 2 trial: changes in daily itch scores
- Linerixibat
  - Ileal bile acid transport (IBAT) inhibitor
  - Primary end point of phase 3 trials: changes in monthly itch scores, adverse effects
- Setanaxib
  - NADP oxidase 1/4 inhibitor
  - Primary end point of phase 3 trials: biochemical response
  - Secondary end points: assessment of fatigue

Fiorucci S et al. *Cells*. 2024;13:1580-1611.

Considerations for Specialty Pharmacists

Anastasia Abramson, PharmD, MBA

Education and Awareness of PBC

Complications of liver disease: Untreated, PBC can lead to liver cirrhosis, hepatocellular carcinoma, liver failure, and death

- 77% 10-year survival in North American and European cohorts
- Both incidence and prevalence have increased over time

Therapy goals aim to rapidly achieve normal serum tests and QOL with prevention of ESLD

- Limited treatment options: 40% of patients have inadequate response to first-line UDCA

Quality of life: Patient QOL is greatly impacted by burden of symptoms that are currently undertreated

Levy C et al. *Clin Gastroenterol Hepatol*. 2023;21(8):2076-2087; Kuiper EM et al. *Gastroenterology*. 2009;136(4):1281-1287; Boonstra K et al. *Liver Int*. 2014;34(6):e31-e38.

Multidisciplinary Care Team and Communication



Liver Cancer Teams. American Liver Foundation. Published September 2022. Accessed December 10, 2024. https://liverfoundation.org/liver-diseases/treatment/know-your-team/

Disease Monitoring and Patient Access

Disease monitoring and therapeutic response may be monitored by biomarkers

- ALP
- Bilirubin

The specialty pharmacist plays an integral role in driving patient access

Capture and reporting of accurate clinical information	Expedite approvals by communicating requirements and missing information with MDO	Reminders to MDO when lab work is due for re-authorization

Lindor KD et al. *Hepatology*. 2019;69(1):394-419.

Specialty Pharmacist Role in PBC Management

How do we support the patient journey to achieve therapy goals?

Drive Adherence

- Manage adverse events
- Manage symptoms
- Identify adherence barriers and counsel on strategies

Patient Education

- Disease state and support resources
- Treatment expectations
- Lifestyle modifications
- Medication information including proper administration, side effects, and drug interactions

Provider Recommendations

- Dose adjustments due to tolerability, drug-drug or drug-disease interactions
- QOL updates and treatment recommendations

Shah NB et al. *PLoS One*. 2019;14(6):e0217798

SP Management of Obeticholic Acid (OCA)

Dose Optimization

- Assess patient response and tolerability after 3 months of therapy to increase to maximum dosage

Routinely monitor patient tolerability and reported changes in pruritus (new onset or worsening)

- Interventions in collaboration with provider:
  - Addition of bile acid binding resins
  - Dose optimization: dosage reduction or temporary interruption
    - If dose interruption, re-start at a reduced dosage

Assess patient-reported adverse events for potential development of hepatic decompensation, portal hypertension, or clinically significant hepatic adverse reactions

- Boxed warning to permanently discontinue therapy
- Educate patient during counsel of s/s to report to their physician

Ocaliva. Prescribing information. Intercept Pharmaceuticals; 2022. Accessed December 10, 2024. https://www.interceptpharma.com/wp-content/uploads/2023/08/Ocaliva_USPI_Clean_VV-REG-040954.pdf

SP Management of Elafibranor

Assess for safety

- Verify female patients of reproductive potential are not pregnant upon therapy initiation
- Provide patient education on adverse effects on fetal and newborn development

Assess patient-reported adverse events for muscle pain or myopathy

- Refer patient and inform provider for clinical exam, CPK measurement, and potential need for therapy interruption

Assess patient-reported adverse events for drug-induced liver injury

- Refer patient to provider for clinical and laboratory evaluation
- Educate patient upon therapy initiation of signs and symptoms to recognize

Medication profile review

- Rifampin-elafibranor
  - Provide reminder to prescriber to monitor patient ALP and bilirubin levels
- Elafibranor-hormonal contraceptives
  - Use effective nonhormonal contraceptives (or add a barrier method) during treatment and for 3 weeks after

Iqirvo. Prescribing information. Ipsen Biopharmaceuticals, Inc; 2024. Accessed December 10, 2024. https://d2rkmuse97gwnh.cloudfront.net/a88aa6d6-3ca0-4362-a711-d53c45ae33ff/c91c4c2d-fbd6-4dec-99db-66768cdb2b5c/c91c4c2d-fbd6-4dec-99db-66768cdb2b5c_source__v.pdf

SP Management of Seladelpar

Assess patient-reported adverse events for hepatic impairment

- Refer patient to provider for clinical and laboratory evaluation
- Educate patient upon therapy initiation of signs and symptoms to recognize

Medication profile review: addition of rifampin to treatment regimen may reduce levels of seladelpar

- Provide reminder to prescriber to monitor patient ALP and bilirubin levels when rifampin is initiated

Adverse event management: caution with OTC recommendations, complete drug interaction check

- Avoid use with OAT3 inhibitors due to increase in seladelpar levels and potential risk for toxicity
- Recommend acetaminophen instead of ibuprofen for headache management

Livdelzi. Prescribing information. Gilead Sciences, Inc; 2024. Accessed December 10, 2024. https://www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.pdf

Itch Severity Assessments

PBC-40

- Itch is one of 6 domains related to PBC
- General topics include scratching until skin is raw, embarrassment from itch, sleep disturbances from itch

5-D Itch

- 5 domains of itching, not validated for PBC
- Evaluates degree, duration, disability, direction, and distribution of itch

NRS

- Provides numerical values of pruritus severity from 0 (no pruritus) to 10 (most severe patient can imagine)

Mayo MJ et al. *Dig Dis Sci*. 2023;68(3):995-1005; Reich A, Szepietowski JC. *Expert Rev Dermatol*. 2013;8(3):291-299.

Specialty Pharmacist Pruritus Assessment

Assess

- Do you have itching?
- How does itching interfere with your lifestyle?
  - Does it affect your sleep or activities?
  - Do you bleed from scratching?
- Would you like treatment for the itching?

Levy C et al. *Clin Gastroenterol Hepatol*. 2023;21(8):2076-2087.

Pruritus Management: Mild Pruritus

Self-management techniques

Avoid

- Hot environments and dry conditions
- Very frequent washing and bathing with hot water
- Overly scented detergents
- Consuming large amounts of hot and/or spicy food, hot drinks, or alcohol
- Tight clothes or clothes made from animal wool

Introduce

- Cold/ lukewarm baths or showers
- Hydrating skin immediately after bathing (unscented)
- Emollients (urea); topical agents with cooling/anesthetic effect
- Wear loose, light clothes made from natural fibers (cotton)
- Maintain low room temperature
- Shorten fingernails to avoid skin damage

Düll MM, Kremer AE. *Clin Liver Dis*. 2022;26(4):727-745; Hirschfield GM et al. *Expert Rev Gastroenterol Hepatol*. 2021;15(8):929-939.

Pruritus Management: Moderate-Severe Pruritus

	Cholestyramine (1st line)	Rifampicin	Naltrexone	Sertraline
Dose Range	4 g to 16 g/day	150 mg to 300 mg BID	12.5 mg titrated to 50 mg/day	75 to 100 mg/day
Pharmacist Clinical Pearls	Interferes with intestinal absorption of other medications (including UDCA) and fat-soluble vitamins; reduces pruritic intensity within 2 weeks	Drug-induced liver injuries have been reported, avoid in patients with bilirubin levels >2.5 mg/dL; monitor ALT/AST at week 2, 6, 12 then q12wk and with dose changes	Gradually introduce and titrate dosage every 3 to 7 days to mitigate potential withdrawal-like reaction to opioid antagonist; induction with IV naltrexone may be completed in-patient with conversion to oral naltrexone; long-term use associated with lowering of pain threshold and unmasking of chronic pains	Monitoring required of sodium and ECG with QT interval
Patient Counseling	Take 1 hour after or 4 hours before other medication to avoid inhibiting absorption; take 20 minutes before meals	Possible but harmless induction of orange-red colored body fluids (urine, stool, or tears)	Withdrawal-like syndrome is usually self-limited	Do not discontinue on your own; keep the pharmacy informed of any changes to medications

Düll MM, Kremer AE. *Clin Liver Dis*. 2022;26(4):727-745; Hirschfield GM et al. *Expert Rev Gastroenterol Hepatol*. 2021;15(8):929-939; Lindor KD, et al. *Hepatology*. 2019;69(1):394-419.

Symptom Management: Fatigue

Sleep hygiene

- Schedule consistency, including weekends and vacations
- Don’t go to bed unless you are sleepy; establish relaxing bedtime routine
- If you don’t fall asleep after 20 minutes, get out of bed; do a quiet activity with low light exposure, avoiding electronics
- Keep the bedroom a comfortable, cool temperature
- Turn off electronics at least 30 minutes before bedtime and limit bright lights in the evenings
- Do not eat large meals before bed; opt for light, healthy snack if hungry
- Avoid afternoon caffeine consumption
- Avoid alcohol before bedtime

Regular exercise

Smoking cessation

Energy management: plan daily activities and tailor them according to the hours when fatigue is experienced

Engage with employer to develop supportive work patterns

Khanna A et al; *Curr Hepatology Rep.* 2019;18:127-133; Hershner S, Shaikh I. Healthy Sleep Habits. Sleep Education. American Academy of Sleep Medicine. Published August 2020. Accessed December 10, 2024. https://sleepeducation.org/healthy-sleep/healthy-sleep-habits/

Symptom Management: Sicca Syndrome

Keratoconjunctivitis sicca (dry eyes):

- Protect eyes from drafts, breezes, and smoky rooms
- Eyeglasses fitted with shields on the sides or wraparound glasses
- Use of humidifiers
- Warm compresses to alleviate discomfort from blepharitis
- Eye drops (artificial tears)

Xerostomia (dry mouth):

- Brush and floss teeth regularly
- Sip on water throughout the day
- Use chewing gum or suck on hard candy (sugar free) to help glands produce more saliva
- Recognize symptoms of thrush and seek care (burning, soreness, white patches inside of mouth)

Levy C et al. *Clin Gastroenterol Hepatol*. 2023;21(8):2076-2087; Sjögren disease. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Published April 7, 2017. Reviewed June 2024. Accessed December 10, 2024. https://www.niams.nih.gov/health-topics/sjogrens-disease/diagnosis-treatment-and-steps-to-take

Patient Engagement

- Telephonic counseling
- Motivational interviewing
- Resource delivery
  - Printed materials
  - Digital materials
- Timing of counseling and resource introduction

Baldoni S et al. *Medicina (Kaunas)*. 2019;55(7); Margolis RH. *The ASHA Leader*. 2004;9(14):10-28; SAMHSA. *Enhancing Motivation for Change in Substance Use Disorder Treatment*. Substance Abuse and Mental Health Services Administration (US); 2019. Accessed December 10, 2024. https://www.ncbi.nlm.nih.gov/books/NBK571068/

Conclusion

- PBC symptoms are undertreated and significantly impact patient quality of life.
- Additional research must focus on the impact of pharmacotherapy in improving symptoms, such as itching and fatigue
- Specialty pharmacists play a vital role in helping patients manage their symptoms, select drug therapies, adhere to medications, manage adverse events, provide patient education, support patient access, and enhance outcomes through medication management.

Additional Resources

Resource	Description
https://impactofcholestaticpruritusitch.com/	Website describing impact of itch in PBC and questions to ask patients
https://livingwithpbc.com/	Patient information and video vignettes describing daily life with PBC
https://mypbcteam.com/	Patient resources including articles about newer treatment options and how to connect with other people living with PBC

Additional Resources



[PBCers Organization – Welcome to our community]



[PBC Foundation | Support for those with Primary Biliary Cholangitis]



[Liver - American Liver Foundation]

Posttest Questions

Posttest Question 1

Which statement is TRUE regarding itching in primary biliary cholangitis (PBC)?

A. The severity of itching correlates with PBC severity.
B. Itching occurs only in the later stages of PBC.
C. The underlying cause of itching in PBC has been fully elucidated.
D. Itching significantly impacts quality of life in patients with PBC.

Posttest Question 2

A 58-year-old woman with a history of PBC presents to your clinic for follow-up. She has been on ursodeoxycholic acid (UDCA) at a dose of 13 mg/kg/day for the past year. Her recent laboratory results show an ALP level of 200 U/L (normal range: 30-120 U/L) and a total bilirubin level of 1.2 mg/dL (normal range: 0.1-1.0 mg/dL). She reports persistent fatigue and moderate pruritus despite treatment with cholestyramine.

What is the most appropriate next step in managing this patient?

A. Continue UDCA monotherapy and re-evaluate in 6 months.

B. Increase the dose of UDCA to 15 mg/kg/day.

C. Initiate treatment with elafibranor 80 mg daily.

D. Initiate treatment with obeticholic acid 5 mg daily.

Posttest Question 3

GC is a 58-year-old woman diagnosed with PBC who has a referral sent to your pharmacy for obeticholic acid. During your initial counseling, GC shares that she has not had any issues with UDCA, but her doctor advised her ALP and bilirubin remain elevated. GC states that lately she has had some itching but wearing cotton clothing usually helps. What is the most appropriate next step?

A. Inform GC she should discontinue UDCA because it isn't helping.
B. Document that GC has mild itching that is helped by wearing cotton. Re-assess GC periodically for any changes in itching severity to identify if additional lifestyle changes or medications are necessary.
C. Document that GC has mild itching that is helped by wearing cotton.
D. Advise GC she should start on cholestyramine right away, taking the obeticholic acid at least 4 hours before or 4 hours after the cholestyramine dose.

Posttest Question 4

After participating in this activity, how confident are you in your knowledge to improve clinical outcomes and alleviate symptoms in patients with PBC?

A. Not at all
B. Somewhat
C. Moderately
D. Very
E. Extremely

Question and Answer Session

Thank you!